NCT00188812

Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease

Open-Label, Multicentre, One Year Extension of the Evaluation of the Safety of Donepezil Hcl in Patients With Dementia Associated With Cerebrovascular Disease

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: —
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: —

Summary

one year extension study following a previous double-blind study to evaluate safety of the drug

Detailed description

A one year extension study for patients who completed E2020-A001-319. Patients will receive 5my donepezil daily for the first 8 weeks and will be assessed by the incidence of advere events, changes in physical exams, ECG and clinical lab determinations. The results will be assessed 6 timues during the year. After 8 week, the investigator may increase the dose to 10mg/day if the patient if the patients show satisfactory tolerability. Six psychometric scales will also be evaluatd.

Conditions

• Dementia Associated With Cerebrovascular Disease

Interventions

Type	Name	Description
DRUG	donepezil hcl

Timeline

• Start date: 2004-05-01
• Completion: 2005-08-01
• First posted: 2005-09-16
• Last updated: 2009-01-12

Locations

1 site across 1 country: Canada